Ars.els-cdn.com



Supplemental MaterialsSupplemental Table 1: Search StrategiesMEDLINE (OvidSP) February 5, 2015MEDLINE#SearchResults1(orthomyxoviridae infections/ or influenza, human/ or expOrthomyxoviridae/ or (flu or flus or grippe* or influenza*).mp.) not haemophilisinfluenzae/ [****Influenza terms****]1029152immunotherapy/ or immunization/ or immunization, passive/ or immunization schedule/ or immunization, secondary/ or immunotherapy, active/ or vaccination/ or mass vaccination/ or Influenza Vaccines/ or (admune or aflunov or afluria or agriflu or agrippal* or alorbat or anflu or antiinfluenza* or "anti-influenza*" or "arepanrix b" or begrivac* or celtura or celvapan or chiromas or daronrix or "flu-vac" or fluad or fluarix or fluax or flublok or fluenz or flugen or flugene or fluinsure or flulaval or flumist or fluogen or flushield or flustat or fluvax or fluviral* or fluvirin* or fluviron or fluzone* or focetria* or gammaflu or grippovac or humenza or idflu or inflexal* or influject or influpozzi or influsplit or influvac* or intanza or "inviron-ol" or invivac or iradogen or mastaflu or "medi 3314" or "medi-3314" or medi3314 or munevan or mutagrip or nivgrip or optaflu or pandemrix or panenza or panvax or "pf 4522625" or "pf-4522625" or pf4522625 or prepandrix or previgrip or pumarix or "skf 106160" or "skf-106160" or skf106160 or vaxigrip or "x-flu").mp. or ((immunization or immunisation or vaccination) adj2 (campaign* or program*)).mp. [****Vaccine terms****]1724993immunotherapy/ec or immunization/ec or immunization, passive/ec or immunization schedule/ec or immunization, secondary/ec or immunotherapy, active/ec or vaccination/ec or mass vaccination/ec or Influenza Vaccines/ec or ((admune or aflunov or afluria or agriflu or agrippal* or alorbat or anflu or antiinfluenza* or "anti-influenza*" or "arepanrix b" or begrivac* or celtura or celvapan or chiromas or daronrix or "flu-vac" or fluad or fluarix or fluax or flublok or fluenz or flugen or flugene or fluinsure or flulaval or flumist or fluogen or flushield or flustat or fluvax or fluviral* or fluvirin* or fluviron or fluzone* or focetria* or gammaflu or grippovac or humenza or idflu or inflexal* or influject or influpozzi or influsplit or influvac* or intanza or "inviron-ol" or invivac or iradogen or mastaflu or "medi 3314" or "medi-3314" or medi3314 or munevan or mutagrip or nivgrip or optaflu or pandemrix or panenza or panvax or "pf 4522625" or "pf-4522625" or pf4522625 or prepandrix or previgrip or pumarix or "skf 106160" or "skf-106160" or skf106160 or vaxigrip or "x-flu" or ((immunization or immunisation or vaccination) adj2 (campaign* or program*))).mp. and ec.fs.) [****Vaccine terms and economics****]414441 and 3 [****Base set 4 economics as floating subheading without outbreaks *****]8915economics/ or exp "costs and cost analysis"/ or economics, behavioral/ or exp economics, hospital/ or hospital charges/ or hospital costs/ or exp economics, medical/ or fees, medical/ or economics, nursing/ or economics, pharmaceutical/ or "fees and charges"/ or fees, pharmaceutical/ or prescription fees/ or ("cost-effectiveness" or "cost-utilit*" or "cost-benefit*" or "cost-minimization*" or "cost-minimisation*" or ((value or net) adj2 benefit*)).mp.25443761 and 2 and 5 [****Base set 3 economics or policy as subject headings without outbreaks*****]76574 or 6 [****maximum universal results****]11398limit 7 to humans11099(orthomyxoviridae infections/ or influenza, human/ or expOrthomyxoviridae/ or (flu or flus or grippe*).mp. [****Influenza Terms****]67784103 and 9 [****Base set 4 economics as floating subheading without outbreaks *****]628119 and 2 and 5 [****Base set 3 economics or policy as subject headings without outbreaks*****]5291210 or 11 [****maximum universal results****]80013limit 12 to humans783EMBASE (Embase Classic+ Embase) 1947 to 2015 week 5EMBASE#SearchResults1exporthomyxovirus infection/ or exp Influenza virus/ or (flu or flus or grippe*).mp. [****Influenza Terms****]1139102immunization/ or active immunization/ or immunoprophylaxis/ or mass immunization/ or vaccination/ or preventive health service/ or influenza vaccination/ or influenza vaccine/ or (admune or aflunov or afluria or agriflu or agrippal* or alorbat or anflu or antiinfluenza* or "anti-influenza*" or "arepanrix b" or begrivac* or celtura or celvapan or chiromas or daronrix or "flu-vac" or fluad or fluarix or fluax or flublok or fluenz or flugen or flugene or fluinsure or flulaval or flumist or fluogen or flushield or flustat or fluvax or fluviral* or fluvirin* or fluviron or fluzone* or focetria* or gammaflu or grippovac or humenza or idflu or inflexal* or influject or influpozzi or influsplit or influvac* or intanza or "inviron-ol" or invivac or iradogen or mastaflu or "medi 3314" or "medi-3314" or medi3314 or munevan or mutagrip or nivgrip or optaflu or pandemrix or panenza or panvax or "pf 4522625" or "pf-4522625" or pf4522625 or prepandrix or previgrip or pumarix or "skf 106160" or "skf-106160" or skf106160 or vaxigrip or "x-flu" or ((immunization or immunisation or vaccination) adj2 (campaign* or program*))).mp. [****Vaccine Terms****]2454853immunization/ec or active immunization/ec or immunoprophylaxis/ec or mass immunization/ec or vaccination/ec or preventive health service/ec or influenza vaccination/ec or influenza vaccine/ec or ((admune or aflunov or afluria or agriflu or agrippal* or alorbat or anflu or antiinfluenza* or "anti-influenza*" or "arepanrix b" or begrivac* or celtura or celvapan or chiromas or daronrix or "flu-vac" or fluad or fluarix or fluax or flublok or fluenz or flugen or flugene or fluinsure or flulaval or flumist or fluogen or flushield or flustat or fluvax or fluviral* or fluvirin* or fluviron or fluzone* or focetria* or gammaflu or grippovac or humenza or idflu or inflexal* or influject or influpozzi or influsplit or influvac* or intanza or "inviron-ol" or invivac or iradogen or mastaflu or "medi 3314" or "medi-3314" or medi3314 or munevan or mutagrip or nivgrip or optaflu or pandemrix or panenza or panvax or "pf 4522625" or "pf-4522625" or pf4522625 or prepandrix or previgrip or pumarix or "skf 106160" or "skf-106160" or skf106160 or vaxigrip or "x-flu" or ((immunization or immunisation or vaccination) adj2 (campaign* or program*))).mp. and ec.fs.) [****Vaccine Terms****]26594exp health economics/ or exp "health care cost"/ or ("cost-effectiveness" or "cost-utilit*" or "cost-benefit*" or "cost-minimization*" or "cost-minimisation*" or ((value or net) adj2 benefit*)).mp. [****Economics****]65390251 and 3104561 and 2 and 4 285375 or 638558limit 7 to human3335CINAHL (EBSCOHost) February 5, 2015CinAHL#SearchResultsS1(MH "Influenza+") OR (MH "Influenza A Virus+") OR (MH "Influenza B Virus") OR (MH "Influenzavirus C") OR (MH "Influenza, Human") OR (MH "Influenza, Seasonal")10844S2(MH "Orthomyxoviridae+")2438S3(MH "Influenza, Seasonal")205S4(MH "Influenza, Pandemic (H1N1) 2009")1195S5(MH "Influenza+") OR (MH "Influenza, Human+") OR (MH "Influenza, Seasonal") OR (MH "Orthomyxoviridae+")10960S6S1 OR S2 OR S3 OR S4 OR S510960S7(MH "Influenza Vaccine")5803S8(MH "Immunization Programs")2855S9(MH "Cost Benefit Analysis") OR (MH "Health Care Costs+") OR (MH "Costs and Cost Analysis+") OR (MH "Health Facility Costs") OR (MH "Cost Control+") OR (MH "Cost Savings") OR (MH "Nursing Costs")56094S10(MH "Economics, Pharmaceutical")1320S11(MH "Product Evaluation") OR (MH "Program Evaluation")25438S12(MH "Fees and Charges") OR (MH "Health Facility Charges")6712S13(MH "Health Systems Agencies") OR (MH "State Health Plans")1503S14(MH "Community Health Workers") OR (MH "Community Health Services+") OR (MH "Community Health Nursing+") OR (MH "Health Resource Utilization") OR (MH "Health Services Needs and Demand+")251914S15S7 OR S88168S16"cost effectiveness"7765S17S9 OR S10 OR S11 OR S12 OR S13 OR S14323411S18(MH "Health Policy") OR (MH "Health Policy Studies")27124S19(MH "Insurance Coverage")3505S20(MH "Economics, Organizations, Control (Non-Cinahl)")875488S21S18 OR S19 OR S20875519S22S6 AND S15 AND S17 AND S21425EBM Review NHS EED/HTA (OvidSP) February 5, 2015NHS EED, HTA #SearchResults1ExpOrthomyxoviridae/ or orthomyxoviridae infections/ or influenza, human/ or (flu or flus or grippe* or influenza*).mp. [****Influenza Terms****]243Grey Matter ListDatabaseKeyword Search TermNumber of HitsResultsCADTHinfluenza58none relevantCochraneinfluenza92none relevantHealth Quality Ontarioinfluenza19none relevantInstitute for Clinical Evaluative Servicesinfluenza62none relevantInstitute of Health Economicsinfluenza71none relevantMcGill University Health Centreinfluenza2none relevantNewfoundland and Labrador Centre for Applied Researchinfluenza4none relevantOttawa Hospital Research Instituteinfluenza26none relevantUBC Therapeutics Initiativeinfluenza2none relevantSupplemental Table 2: Quality Appraisal Summary Table – SIGN QuestionsAuthor, year?Quality Rating(1) The study addresses an appropriate and clearly focused question(2) The economic importance of the question is clear(3) The choice of study design is justified(4) All costs that are relevant from the viewpoint of the study are included and are measured and valued appropriately(5) The outcome measures used to answer the study question are relevant to that purpose and are measured and valued appropriately(6) If discounting of future costs and outcomes is necessary, it been performed correctly(7) Assumptions are made explicit and a sensitivity analysis performed(8) The decision rule is made explicit and comparisons are made on the basis of incremental costs and outcomes.(9) The results provide information of relevance to policy makersHealthy Working AdultsAballéa 2006 (French)AcceptableyynyynyyyAballéa 2007 (Int'l)High qualityyynyynyyyAbelléa 2007 (Spain)High qualityyynyynyyyBuxton-Bridges 2000AcceptableyynyyncyyLee, 2002AcceptableyynycnyyyMaciosek 2006AcceptableyynyynyynMogasale 2011AcceptableyynyyyyyyNewall 2008AcceptableyynyyyyyyNichol 2001AcceptableyyyyyyyyyNichol 2003AcceptableyyyycnyyyTurner 2006AcceptableyyyyynyyyChildren & AdolescentsCohen G, 2000AcceptableyynyycyyyEsposito 2006AcceptableyynyyncyyLuce 2001AcceptableycnyynyyyMarchetti 2007AcceptableyynyynyyyNavas 2007Acceptableyynyyyyyyy = yes; n = no; c = cannot determine, unclearAuthor, year?Quality Rating (1) The study addresses an appropriate and clearly focused question(2) The economic importance of the question is clear(3) The choice of study design is justified(4) All costs that are relevant from the viewpoint of the study are included and are measured and valued appropriately(5) The outcome measures used to answer the study question are relevant to that purpose and are measured and valued appropriately(6) If discounting of future costs and outcomes is necessary, it been performed correctly(7) Assumptions are made explicit and a sensitivity analysis performed(8) The decision rule is made explicit and comparisons are made on the basis of incremental costs and outcomes.(9) The results provide information of relevance to policy makersChildrenPitman 2013High qualityyyyyynyyyProsser 2006AcceptableyyncynyyySalleras, 2009High qualityyynycyyyySalo 2006AcceptableyyncyncyySchimier 2008AcceptableyynnyyyyyHigh RiskAvritscher, 2007High qualityyynyyyyyyBlommaert 2014AcceptableyynyyyyyyNichol 2002AcceptableyynyycyyyOverallClements 2011AcceptableyyyyyyyyySander 2010High qualityyynyyyyyyPregnant & Post-PartumBeigi 2009AcceptableyynyynyyyDing 2012AcceptableyynycnyyyJit 2010AcceptableyynyynyyyRoberts 2006AcceptableyynyynyyySkedgel 2011High qualityyynyyyyyyy = yes; n = no; c = cannot determine, unclearAuthor, year?Quality Rating (1) The study addresses an appropriate and clearly focused question(2) The economic importance of the question is clear(3) The choice of study design is justified(4) All costs that are relevant from the viewpoint of the study are included and are measured and valued appropriately(5) The outcome measures used to answer the study question are relevant to that purpose and are measured and valued appropriately(6) If discounting of future costs and outcomes is necessary, it been performed correctly(7) Assumptions are made explicit and a sensitivity analysis performed(8) The decision rule is made explicit and comparisons are made on the basis of incremental costs and outcomes.(9) The results provide information of relevance to policy makersRejectedCicchetti, 2010UnacceptableyynccnycyCampbell 1997UnacceptableynnnnnnnnCohen P, 2003UnacceptableyynyynyycColombo, 2006UnacceptableyynycnyyyKumpulainen 1997UnacceptableyynncnncnMeltzer 2005UnacceptableyyncynyncParlevliet, 2002UnacceptableyynccnynnScott, 1996UnacceptableyynnnnnycTeufel, 2008UnacceptableyccncncynYoo, 2013Unacceptableycnynnnyny = yes; n = no; c = cannot determine, unclearSupplemental Table 3: Quality Appraisal – Vaccine Related QuestionsAuthor, year?Quality Rating (1) Details of vaccine administration were clearly stated(2) Was an appropriate definition of vaccine efficacy/effectiveness provided and referenced?(3) Were vaccine safety and adverse events considered?(4) Vaccine wastage was considered in the study(5) Indirect effects such as community or herd immunity are considered in the conclusionsHealthy Working AdultsAballéa 2006 (French)AcceptableyycnnAballéa 2007 (Int'l)High qualityyycnnAbelléa 2007 (Spain)High qualityyynnnBuxton-Bridges 2000AcceptableyyynnLee, 2002AcceptableyynnnMaciosek 2006Acceptableyynyy*Mogasale 2011AcceptableyynynNewall 2008AcceptableyyyynNichol 2001AcceptableyyynnNichol 2003AcceptableycynnTurner 2006AcceptableyyynnChildren & AdolescentsCohen G, 2000AcceptableyyynnEsposito 2006AcceptableyyynnLuce 2001Acceptableyyy ny*Marchetti 2007AcceptableyyynyNavas 2007AcceptableyyynnPitman 2013High qualityyycnyy = yes; n = no; c = cannot determine, unclear; y* = addressed but not included in analysisAuthor, year?Quality Rating (1) Details of vaccine administration were clearly stated(2) Was an appropriate definition of vaccine efficacy/effectiveness provided and referenced?(3) Were vaccine safety and adverse events considered?(4) Vaccine wastage was considered in the study(5) Indirect effects such as community or herd immunity are considered in the conclusionsChildren/AdolescntProsser 2006Acceptableynyny*Salleras, 2009High qualityyyyny*Salo 2006Acceptableyynny*Schimier 2008Acceptableyyyny*High RiskAvritscher, 2007High qualityyyynnBlommaert 2014Acceptableyynny*Nichol 2002AcceptableyynnnOverallClements 2011AcceptableyyynySander 2010High qualityyyynyPregnant & Post-PartumBeigi 2009Acceptablecyyny*Ding 2012AcceptableynynnJit 2010AcceptableyyyyyRoberts 2006AcceptableyyynnSkedgel 2011High qualityyyynyy = yes; n = no; c = cannot determine, unclear; y* = addressed but not included in analysisAuthor, year?Quality Rating (1) Details of vaccine administration were clearly stated(2) Was an appropriate definition of vaccine efficacy/effectiveness provided and referenced?(3) Were vaccine safety and adverse events considered?(4) Vaccine wastage was considered in the study(5) Indirect effects such as community or herd immunity are considered in the conclusionsRejectedCicchetti, 2010UnacceptablennnnnCampbell 1997UnacceptableyyynnCohen P, 2003UnacceptableyyycnColombo, 2006Unacceptableyyycy*Kumpulainen 1997UnacceptablenynnnMeltzer 2005UnacceptablennynnParlevliet, 2002UnacceptableyynnnScott, 1996UnacceptableynnnnTeufel, 2008UnacceptableyynnnYoo, 2013Unacceptableynnnny = yes; n = no; c = cannot determine, unclear; y* = addressed but not included in analysis ................
................

In order to avoid copyright disputes, this page is only a partial summary.

Google Online Preview   Download